Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1)

What Was Tested

Researchers studied Endothelin-1 in this randomized controlled trial publication.

Low sFlt-1 (soluble Fms-like tyrosine kinase-1) and ET-1 (endothelin-1) levels have been reported in preeclamptic women using proton pump inhibitors.

Who Took Part

The abstract describes 20 women taking part.

PubMed indexes the participants as infants and adults, women only.

Primary outcome was specified as the difference in sFlt-1, PlGF, or CT-proET-1 after 4 days of omeprazole versus 20 preeclamptic women not receiving omeprazole.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Endothelin-1 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The methods mention a period of 4 days.

What Was Measured

Low sFlt-1 (soluble Fms-like tyrosine kinase-1) and ET-1 (endothelin-1) levels have been reported in preeclamptic women using proton pump inhibitors.

Topics PubMed links to this paper include Biomarkers, Endothelin-1, Esomeprazole, Omeprazole, Placenta, Placenta Growth Factor and Pre-Eclampsia.

Author keywords: adult, maternal age and perfusion.

What This Means in Plain Language

The paper is a randomized study of Endothelin-1 in 20 women over 4 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the Endothelin-1 compound page, all human trials.